Advanced Biological Research Group to Study Effects of mRNA on Women’s Reproduction
JACKSONVILLE, Fla., June 5, 2025 /PRNewswire/ -- Advanced Biological Research Group (ABRG), a 501c3, has announced its second study to...
Vaccine
Elanco Releases New Report Highlighting the Significance of America’s Itchy Dogs and the Need for Itch Relief
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data...
DIOSynVax Presents Its Technology at the Invitation-Only Next Venture Capital Unit (VCU) Health Tech Showcase at the London Stock Exchange
CAMBRIDGE, United Kingdom and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- DIOSynVax, a clinical-stage biotechnology company at the forefront...
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,...
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in...
Elicio Therapeutics Secures $10 Million in Financing
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June...
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s...
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Figure_1 Figure 1: Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in CoTikiS...
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today...
FSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free Funds
FSA Store recommends three steps to help account holders avoid forfeiting unused funds to the June 30 deadline – a...
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered...
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented...
Rapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors
Burlington, Ontario--(Newsfile Corp. - June 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced...
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable...
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30,...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of...